Results of a new study published in the Annals of Internal Medicine [Ann Intern Med 152:505-512, 2010] indicate that the risk for false-positive results of CT lung cancer screening tests is substantial. Led by Jennifer M. Croswell, MD, researchers from NCI sought to quantify the cumulative risk in a 1- or 2-year lung cancer screening exam, based on at least one false-positive finding.
Results of a new study published in the Annals of Internal Medicine [Ann Intern Med 152:505-512, 2010] indicate that the risk for false-positive results of CT lung cancer screening tests is substantial. Led by Jennifer M. Croswell, MD, researchers from NCI sought to quantify the cumulative risk in a 1- or 2-year lung cancer screening exam, based on at least one false-positive finding. In addition to determining the rates of false-positive findings, the investigators identified rates of unnecessary diagnostic procedures that are potentially brought on by these false-positive findings. The randomized controlled trial of low-dose CT vs chest radiography (ClinicalTrials.gov registration number: NCT00006382) found that the risks of false-positive results of lung cancer screening tests are substantial after only two annual examinations, particularly for low-dose CT. The authors recommended further study of resulting economic, psychosocial, and physical burdens of these methods.
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.